My primary research
interests concern the regulation of smooth muscle cell growth and
vascular reactivity. I have developed models of vascular injury
and am using them to study the changes in smooth muscle cells and
the surrounding matrix on growth factor signaling. The relationship
between contractile agonists such as angiotensin and endothelin
and growth factors signaling is also under investigation. I am particularly
interested in the potential differences in control of growth in
normal vessel wall compared to a diseased (atherosclerotic) vessel.
In addition, we are comparing the response to growth factors in
cell culture vs. in vivo systems. The second messenger pathways
and cell cycle control points for a number of growth factors are
being actively examined in vascular smooth muscle cells. Using inhibitors
of various steps in the signaling cascade we hope to devise effective
strategies for regulating smooth muscle cell growth in vivo. Representative Publications: Keiser, JA, M Ryan, R Panek, J Hodges, I Sircar. Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther 272: 963-969, 1995. Davis LS, SJ Haleen, AM Doherty, WL Cody and JA Keiser. Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin. J Amer Soc Nephrol 268: 372-279, 1994. .
|
